athenahealth acquisition marks entry to hospital market

athenahealth will acquire RazorInsights, a leader in cloud-based EHR and financial solutions for rural, critical access and community hospitals.

The acquisition marks athenahealth's entry into the hospital market, specifically the 50-bed-and-under inpatient care environment, which accounts for approximately one-third of the U.S. hospital market. athenahealth has been a market leader in the ambulatory space, serving more than 59,000 providers and achieving best-in-class recognition.

athenahealth expects this acquisition to accelerate its work to advance connectedness across the care continuum, according to a release.

"Today's hospital market is woefully underserved when it comes to IT systems and IT partners that are accountable for reducing costs, increasing quality, and enabling a better patient experience," said Jonathan Bush, chairman and CEO. "With RazorInsights, athenahealth will immediately be injected into the inpatient care environment; this is a natural extension for our cloud-based services, will tremendously grow our network knowledge, and will accelerate our introduction of results-oriented, inpatient solutions that hospitals can confidently invest in and demand accountability from."

Both companies offer cloud-based solutions as an alternative to on-premise software implementations, which require large upfront and ongoing expenditures to install and operate.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.